Hepion Pharmaceuticals Company Profile - aVenture Research
Hepion Pharmaceuticals is a biotechnology company, the former ContraVir Pharmaceuticals spun off from Synergy Pharmaceuticals, that develops diagnostic and therapeutic candidates for serious liver, immune, and inflammatory diseases alongside a transcript-reading liver cancer assay and two delivery-focused therapeutic programs. Its therapeutics are GV104, a transmucosal buccal film of an approved opioid antagonist in clinical development, and GV023, an oral formulation of infliximab, an approved anti-TNF antibody.
The assay reads actively expressed tumor transcripts rather than proteins shed into the blood, for early detection of hepatocellular carcinoma in high-risk cirrhotic patients. Both therapeutic programs apply new delivery methods to compounds already approved for human use.
Hepion Pharmaceuticals is a biotechnology company developing an assay for early liver cancer in high-risk cirrhotic patients and therapeutic candidates.